scholarly article | Q13442814 |
P50 | author | Rafael de la Camara | Q60628685 |
F Márquez-Malaver | Q83200296 | ||
Teresa Caballero-Velazquez | Q90262472 | ||
Christelle Ferrà | Q90463753 | ||
Virginia Escamilla Gómez | Q91174325 | ||
Irene García Cadenas | Q91174327 | ||
Paula Molés | Q91174331 | ||
P2093 | author name string | Estefanía Pérez | |
Jorge Sierra | |||
Guillermo Orti | |||
Valentín García-Gutiérrez | |||
Blanca Molina Angulo | |||
José A Pérez-Simón | |||
David Valcárcel Ferreiras | |||
Marc Poch | |||
Grupo Español de Trasplante Hematopoyético (GETH) | |||
Marta González Vicent | |||
Ingrid M Parra Salinas | |||
Dolores Caballero Barrigón | |||
Ildefonso Espigado Tocino | |||
Lucía López Corral | |||
Ariadna Pérez Martínez | |||
Cristina Calderón Cabrera | |||
Isabel Sánchez Ortega | |||
Jaime Sanz Caballer | |||
Juan Montoro Gómez | |||
Kyra Velázquez-Kennedy | |||
María C Viguria Alegría | |||
María João Mende | |||
María T Zudaire Ripa | |||
Miguel A Díaz Pérez | |||
Nancy Rodríguez Torres | |||
Pedro A González Sierra | |||
Rocío Parody Porras | |||
Rodrigo Martino Bofarull | |||
Silvanna Saavedra Gerosa | |||
P2860 | cites work | Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease | Q49724160 |
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. | Q50092012 | ||
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD | Q58782275 | ||
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms | Q60044478 | ||
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
Extracorporeal Photopheresis: Tolerogenic or Immunogenic Cell Death? Beyond Current Dogma | Q26798468 | ||
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
Current issues in chronic graft-versus-host disease | Q33917187 | ||
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 | ||
Steroid-Refractory Acute GVHD: Predictors and Outcomes. | Q35550596 | ||
Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis | Q35760517 | ||
Rituximab for steroid-refractory chronic graft-versus-host disease | Q35848933 | ||
Acute graft versus host disease | Q36059671 | ||
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 | ||
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. | Q36363380 | ||
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor | Q36554724 | ||
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 | ||
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. | Q37468247 | ||
Diagnosis and Staging of Chronic Graft-versus-Host Disease in the Clinical Practice | Q37778478 | ||
Extracorporeal photopheresis in acute and chronic graft-versus-host disease | Q38208102 | ||
Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review | Q38701847 | ||
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease | Q43228479 | ||
Rapamycin for refractory acute graft-versus-host disease | Q43246106 | ||
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy | Q46428638 | ||
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease. | Q48259698 | ||
P433 | issue | 3 | |
P921 | main subject | ruxolitinib | Q7383611 |
P304 | page(s) | 641-648 | |
P577 | publication date | 2019-11-07 | |
P1433 | published in | Bone Marrow Transplantation | Q4941523 |
P1476 | title | Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study | |
P478 | volume | 55 |
Q89767651 | Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults | cites work | P2860 |
Search more.